Berlin, Germany: The cell and gene therapy industry is witnessing another major regulatory development as UniQure moves closer to seeking FDA approval for its Huntington’s disease gene therapy, AMT-130. The decision reflects a significant shift in the FDA’s approach toward advanced genetic medicines and could influence how future gene therapy programs are evaluated.
UniQure announced that recent discussions with FDA officials created alignment around using three years of clinical trial data to support its upcoming marketing application.
The company now plans to submit its approval application between July and September 2026, marking a major milestone for one of the most closely followed gene therapy programs in development.
AMT-130 is designed to target Huntington’s disease, a rare and progressive neurological disorder caused by genetic mutations. In its clinical study, UniQure evaluated two different dose levels of AMT-130 across 29 patients and compared outcomes against an external control group. The results showed promising signs, with patients receiving the higher dose experiencing a significant slowdown in disease progression after three years of treatment.
The data created strong excitement among patients, researchers, and investors, as it highlighted the potential of gene therapy to transform treatment approaches for rare genetic diseases.
However, the journey toward approval was not straightforward. Earlier discussions with the FDA raised concerns about the strength of the available evidence.
The agency questioned aspects of the trial design, including the use of external control data instead of a traditional randomized control group. At one stage, FDA officials recommended that UniQure conduct an additional trial involving a sham surgery control group before submitting the approval application.
This created uncertainty around AMT-130’s regulatory future and raised broader concerns across the gene therapy sector about the challenges companies face while bringing innovative therapies to market.
The situation became more complex after changes in FDA leadership, including the departures of key officials involved in drug and gene therapy regulation.
Following these leadership changes, analysts believe the FDA may now be taking a more flexible approach toward certain advanced therapy approvals.
UniQure’s latest update has therefore become more than just a company-specific development. It represents a potential shift in the regulatory environment for cell and gene therapy companies developing breakthrough treatments. Investors reacted positively to the announcement, with UniQure’s stock price increasing significantly after the company confirmed its planned FDA submission timeline.
The development also brings attention to other biotechnology companies working on gene editing, cell therapy, rare disease treatments, and next-generation genetic medicines.
For decision-makers across biotechnology, pharmaceuticals, and healthcare investment, tracking regulatory movements, clinical progress, funding activity, partnerships, and pipeline developments has become increasingly important.
The cell and gene therapy continues to expand rapidly, with hundreds of companies developing innovative platforms across areas such as gene replacement, gene editing, CAR-T therapies, stem cell therapies, and personalized medicines.
Understanding which companies are advancing clinical trials, securing investments, building partnerships, and approaching regulatory milestones can provide valuable strategic insights.
Towards Healthcare Research and Consulting provides dashboard that helps decision-makers monitor 100+ cell and gene therapy companies, tracking their pipelines, therapeutic segments, clinical developments, investments and partnerships; available under one dashboard: https://www.towardshealthcare.com/cell-gene-intelligence-platform
About UniQure
uniQure is a clinical-stage biotechnology company specializing in AAV-based gene therapies for severe genetic and neurological diseases. Headquartered in Amsterdam, the company is known for developing Glybera, the first gene therapy approved in Europe. Its pipeline is focused on areas such as Huntington’s disease and epilepsy, with AMT-130 emerging as a leading gene therapy candidate for Huntington’s disease. The company also operates its own gene therapy manufacturing infrastructure to support future commercialization efforts.
Resource:
https://www.uniqure.com/investors-media/press-releases
https://www.towardshealthcare.com/
https://www.towardshealthcare.com/cell-gene-intelligence-platform